Insights

Strategic Focus Targeting neonatal white matter injury with TT-20 positions Tellus Therapeutics at the intersection of perinatal care and neuroregeneration, presenting a clear outreach path to academic medical centers, NICUs, and pediatric neurology departments researching white matter injury and myelin repair.

Regulatory Path Pursuing a novel regulatory path to evaluate safety and efficacy in newborns indicates opportunities to engage with regulatory consultants, contract research organizations, and early dialogue with pediatric and neonatal oversight bodies to accelerate IND-enabling activities.

Funding Momentum Recent Series A funding and seed investments demonstrate investor confidence and potential for co-development or milestone-based partnerships with pharma or biotechs seeking to expand into neonatal neurotherapeutics.

Clinical & Market Need unmet need for first-in-class treatments for white matter injury in preterm infants creates a strong value proposition for payer discussions and health economic analyses to support adoption once safety/efficacy signals are established.

Partnership Readiness Small team size combined with a lead program in TT-20 makes Tellus an attractive partner for CROs, academic consortia, and biotech players seeking externalization of IND-enabling work and joint development to de-risk early-stage trials.

Similar companies to Tellus Therapeutics, Inc

Tellus Therapeutics, Inc Tech Stack

Tellus Therapeutics, Inc uses 8 technology products and services including gstatic.com, WordPress, Microsoft 365, and more. Explore Tellus Therapeutics, Inc's tech stack below.

  • gstatic.com
    Content Delivery Network
  • Content Management System
  • JSON-LD
    Javascript Frameworks
  • Mailcheck
    Javascript Libraries
  • Google Tag Manager
    Tag Management
  • Web Platform Extensions
  • jQuery Validation Plugin
    Web Tools And Plugins

Tellus Therapeutics, Inc's Email Address Formats

Tellus Therapeutics, Inc uses at least 1 email format:
Tellus Therapeutics, Inc Email FormatsExamplePercentage
FirstLast@tellustherapeutics.comJohnDoe@tellustherapeutics.com
100%

Frequently Asked Questions

What is Tellus Therapeutics, Inc's official website and social media links?

Minus sign iconPlus sign icon
Tellus Therapeutics, Inc's official website is tellustherapeutics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Tellus Therapeutics, Inc generate?

Minus sign iconPlus sign icon
As of November 2026, Tellus Therapeutics, Inc's annual revenue is estimated to be $1M - $10M.

What is Tellus Therapeutics, Inc's SIC code and NAICS code?

Minus sign iconPlus sign icon
Tellus Therapeutics, Inc's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Tellus Therapeutics, Inc have currently?

Minus sign iconPlus sign icon
As of November 2026, Tellus Therapeutics, Inc has approximately 6 employees across 1 continents, including North America. Key team members include Co-Founder And Ceo: J. K. Explore Tellus Therapeutics, Inc's employee directory with LeadIQ.

What industry does Tellus Therapeutics, Inc belong to?

Minus sign iconPlus sign icon
Tellus Therapeutics, Inc operates in the Biotechnology Research industry.

What technology does Tellus Therapeutics, Inc use?

Minus sign iconPlus sign icon
Tellus Therapeutics, Inc's tech stack includes gstatic.com, WordPress, Microsoft 365, JSON-LD, Mailcheck, Google Tag Manager, MailChimp for WordPress and jQuery Validation Plugin.

What is Tellus Therapeutics, Inc's email format?

Minus sign iconPlus sign icon
Tellus Therapeutics, Inc's email format typically follows the pattern of FirstLast@tellustherapeutics.com. Find more Tellus Therapeutics, Inc email formats with LeadIQ.

How much funding has Tellus Therapeutics, Inc raised to date?

Minus sign iconPlus sign icon
As of November 2026, Tellus Therapeutics, Inc has raised $53M in funding. The last funding round occurred on Feb 21, 2023 for $16M.

When was Tellus Therapeutics, Inc founded?

Minus sign iconPlus sign icon
Tellus Therapeutics, Inc was founded in 2018.
Tellus Therapeutics, Inc logo

Tellus Therapeutics, Inc

Biotechnology ResearchNorth Carolina, United States2-10 Employees

Tellus Therapeutics is a small biotechnology company based in Durham, North Carolina. It develops novel small molecules derived from human maternal breast milk to treat newborns with perinatal brain injury. Its lead candidate, TT-20, aims to promote regeneration of myelin-producing oligodendrocytes to support white matter repair. Preclinical studies have shown TT-20 reverses white matter injury in animal models of perinatal brain injury and multiple sclerosis. The company is pursuing a regulatory pathway to evaluate the safety and efficacy of TT-20 in newborns with brain injury. Operating within the biotechnology research sector, Tellus Therapeutics focuses on neonatal brain injury and myelin repair.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
2-10

Section iconFunding & Financials

  • $53M

    Tellus Therapeutics, Inc has raised a total of $53M of funding over 8 rounds. Their latest funding round was raised on Feb 21, 2023 in the amount of $16M as a Venture Round.

  • $1M - $10M

    Tellus Therapeutics, Inc's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.